Association of tobacco product use with chronic obstructive pulmonary disease (COPD) prevalence and incidence in Waves 1 through 5 (2013–2019) of the Population Assessment of Tobacco and Health (PATH) Study
Tóm tắt
We examined the association of non-cigarette tobacco use on chronic obstructive pulmonary disease (COPD) risk in the Population Assessment of Tobacco and Health (PATH) Study. There were 13,752 participants ≥ 40 years with Wave 1 (W1) data for prevalence analyses, including 6945 adults without COPD for incidence analyses; W1–5 (2013–2019) data were analyzed. W1 tobacco use was modeled as 12 mutually-exclusive categories of past 30-day (P30D) single and polyuse, with two reference categories (current exclusive cigarette and never tobacco). Prevalence and incidence ratios of self-reported physician-diagnosed COPD were estimated using weighted multivariable Poisson regression. W1 mean (SE) age was 58.1(0.1) years; mean cigarette pack-years was similar for all categories involving cigarettes and exclusive use of e-cigarettes (all > 20), greater than exclusive cigar users (< 10); and COPD prevalence was 7.7%. Compared to P30D cigarette use, never tobacco, former tobacco, and cigar use were associated with lower COPD prevalence (RR = 0.33, (95% confidence interval—CI) [0.26, 0.42]; RR = 0.57, CI [0.47, 0.70]; RR = 0.46, CI [0.28, 0.76], respectively); compared to never tobacco use, all categories except cigar and smokeless tobacco use were associated with higher COPD prevalence (RR former = 1.72, CI [1.33, 2.23]; RR cigarette = 3.00, CI [2.37, 3.80]; RR e-cigarette = 2.22, CI [1.44, 3.42]; RR cigarette + e-cigarette = 3.10, CI [2.39, 4.02]; RR polycombusted = 3.37, CI [2.44, 4.65]; RR polycombusted plus noncombusted = 2.75, CI]1.99, 3.81]). COPD incidence from W2-5 was 5.8%. Never and former tobacco users had lower COPD risk compared to current cigarette smokers (RR = 0.52, CI [0.35, 0.77]; RR = 0.47, CI [0.32, 0.70], respectively). Compared to never use, cigarette, smokeless, cigarette plus e-cigarette, and polycombusted tobacco use were associated with higher COPD incidence (RR = 1.92, CI [1.29, 2.86]; RR = 2.08, CI [1.07, 4.03]; RR = 1.99, CI [1.29, 3.07]; RR = 2.59, CI [1.60, 4.21], respectively); exclusive use of e-cigarettes was not (RR = 1.36, CI [0.55, 3.39]). E-cigarettes and all use categories involving cigarettes were associated with higher COPD prevalence compared to never use, reflecting, in part, the high burden of cigarette exposure in these groups. Cigarette—but not exclusive e-cigarette—use was also strongly associated with higher COPD incidence. Compared to cigarette use, only quitting tobacco was protective against COPD development.
Tài liệu tham khảo
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2022).
Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011;11(1):36.
Claire SS, Gouda H, Schotte K, et al. Lung health, tobacco, and related products: gaps, challenges, new threats, and suggested research. Am J Physiol Lung Cell Mol Physiol. 2020;318(5):L1004–7.
Hajek P, Phillips-Waller A, Przulj D, et al. A randomized trial of E-cigarettes versus nicotine-replacement therapy. N Engl J Med. 2019;380(7):629–37.
Polosa R, Rodu B, Caponnetto P, Maglia M, Raciti C. A fresh look at tobacco harm reduction: the case for the electronic cigarette. Harm Reduct J. 2013;10:19.
Polosa R, Morjaria JB, Prosperini U, et al. Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up. Int J Chron Obstruct Pulmon Dis. 2018;13:2533–42.
Polosa R, Morjaria JB, Prosperini U, et al. COPD smokers who switched to e-cigarettes: health outcomes at 5-year follow up. Ther Adv Chronic Dis. 2020;11:2040622320961617.
Perez MF, Atuegwu NC, Mead EL, Oncken C, Mortensen EM. Adult e-cigarettes use associated with a self-reported diagnosis of COPD. Int J Environ Res Public Health. 2019;16(20):3938.
Wills TA, Pagano I, Williams RJ, Tam EK. E-cigarette use and respiratory disorder in an adult sample. Drug Alcohol Depend. 2019;194:363–70.
Osei AD, Mirbolouk M, Orimoloye OA, et al. Association between E-Cigarette use and chronic obstructive pulmonary disease by smoking status: behavioral risk factor surveillance system 2016 and 2017. Am J Prevent Med. 2020;58(3):336–42.
Xie Z, Ossip DJ, Rahman I, Li D. Use of electronic cigarettes and self-reported chronic obstructive pulmonary disease diagnosis in adults. Nicotine Tob Res. 2020;22(7):1155–61.
Bhatta DN, Glantz SA. Association of e-cigarette use with respiratory disease among adults: a longitudinal analysis. Am J Prev Med. 2019;58(2):182–90.
Xie W, Kathuria H, Galiatsatos P, et al. Association of electronic cigarette use with incident respiratory conditions among US adults from 2013 to 2018. JAMA Netw Open. 2020;3(11):e2020816–e2020816.
Shi H, Tavárez ZQ, Xie Z, et al. Association of flavored electronic nicotine delivery system (ENDS) use with self-reported chronic obstructive pulmonary disease (COPD): results from the Population Assessment of Tobacco and Health (PATH) study, Wave 4. Tob Induc Dis. 2020;18:82.
Rodriguez J, Jiang R, Johnson WC, MacKenzie BA, Smith LJ, Barr RG. The association of pipe and cigar use with cotinine levels, lung function, and airflow obstruction: a cross-sectional study. Ann Intern Med. 2010;152(4):201–10.
Hyland A, Ambrose BK, Conway KP, et al. Design and methods of the Population Assessment of Tobacco and Health (PATH) Study. Tob Control. 2017;26(4):371–8.
Tourangeau R, Yan T, Sun H, Hyland A, Stanton CA. Population Assessment of Tobacco and Health (PATH) reliability and validity study: Selected reliability and validity estimates. Tob Control. 2019;28(6):663–8.
Piesse A, Opsomer J, Dohrmann S, et al. Longitudinal uses of the population assessment of tobacco and health study. Tob Regul Sci. 2021;7(1):3–16.
Tilert T, Dillon C, Paulose-Ram R, Hnizdo E, Doney B. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007–2010. Respir Res. 2013;14:103.
Tilert T, Paulose-Ram R, Howard D, Butler J, Lee S, Wang MQ. Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40–79: the National Health and Nutrition Examination Survey (NHANES) 2007–2012. EC Pulmonol Respir Med. 2018;7(9):650–62.
Couper D, Lavange LM, Han M, et al. Design of the subpopulations and intermediate outcomes in COPD Study (SPIROMICS). Thorax. 2013;69(5):492–5.
Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD. 2010;7(1):32–43.
United States Department of Health Human Services, National Institutes of Health, National Institute on Drug Abuse, United States Department of Health Human Services, Food Drug Administration, Center for Tobacco Products. Population Assessment of Tobacco and Health (PATH) Study [United States] Restricted-Use Files. In: Inter-university Consortium for Political and Social Research [distributor]; 2021.
Wu J-J, Xu H-R, Zhang Y-X, et al. The characteristics of the frequent exacerbators with chronic bronchitis phenotype and the asthma-chronic obstructive pulmonary disease overlap syndrome phenotype in chronic obstructive pulmonary disease patients: a meta-analysis and system review. Medicine. 2019;98(46):e17996–e17996.
Eisner MD, Iribarren C, Yelin EH, et al. The impact of SHS exposure on health status and exacerbations among patients with COPD. Int J Chron Obstruct Pulmon Dis. 2009;4:169–76.
Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana Use, Respiratory Symptoms, and Pulmonary Function: A Systematic Review and Meta-analysis. Ann Intern Med. 2018;169(2):106–15.
Putcha N, Puhan MA, Drummond MB, et al. A simplified score to quantify comorbidity in COPD. PLoS ONE. 2014;9(12): e114438.
McCarthy PJ. Pseudoreplication: further evaluation and applications of the balanced half-sample technique. 1969.
Judkins DR. Fay’s method for variance estimation. Journal of Official Statistics. 1990;6(3):223.
Stata Statistical Software: Release 17. [computer program]. College Station, TX: StataCorp LLC; 2019.
Office of the Surgeon G, Office on S, Health. Reports of the Surgeon General. In: The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2004.
Sakamaki-Ching S, Williams M, Hua M, et al. Correlation between biomarkers of exposure, effect and potential harm in the urine of electronic cigarette users. BMJ Open Respir Res. 2020;7(1): e000452.
Song MA, Freudenheim JL, Brasky TM, et al. Biomarkers of exposure and effect in the lungs of smokers, nonsmokers, and electronic cigarette users. Cancer Epidemiol. 2020;29(2):443–51.
Olmedo P, Goessler W, Tanda S, et al. Metal concentrations in e-cigarette liquid and aerosol samples: the contribution of metallic coils. EnvironHealth Perspect. 2018;126(2): 027010.
Bozier J, Rutting S, Xenaki D, Peters M, Adcock I, Oliver BG. Heightened response to e-cigarettes in COPD. ERJ Open Research. 2019;5(1):00192–2018.
Pleasants RA, Rivera MP, Tilley SL, Bhatt SP. Both duration and pack-years of tobacco smoking should be used for clinical practice and research. Ann Am Thorac Soc. 2020;17(7):804–6.
Gershon AS, Hwee J, Chapman KR, et al. Factors associated with undiagnosed and overdiagnosed COPD. Eur Respir J. 2016;48(2):561–4.
Iribarren C, Tekawa IS, Sidney S, Friedman GD. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999;340(23):1773–80.
Baker F, Ainsworth SR, Dye JT, et al. Health risks associated with cigar smoking. JAMA. 2000;284(6):735–40.
Edwards KC, Sharma E, Halenar MJ, et al. Longitudinal pathways of exclusive and polytobacco cigar use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1–3 (2013–2016). Tob Control. 2020;29(Suppl 3):s163–9.
Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130–9.
Ho T, Cusack RP, Chaudhary N, Satia I, Kurmi OP. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019;15(1):24–35.
Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–63.
Syamlal G, Doney B, Mazurek JM. Chronic obstructive pulmonary disease prevalence among adults who have never smoked, by industry and occupation—United States, 2013–2017. Morb Mortal Wkly Rep. 2019;68(13):303.
Taylor KA, Sharma E, Edwards KC, et al. Longitudinal pathways of exclusive and polytobacco cigarette use among youth, young adults and adults in the USA: findings from the PATH Study Waves 1–3 (2013–2016). Tob Control. 2020;29(Suppl 3):s139–46.